NASDAQ:VRDN Viridian Therapeutics (VRDN) Stock Price, News & Analysis $14.09 +0.62 (+4.60%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$13.43▼$14.3450-Day Range$12.16▼$17.2952-Week Range$10.93▼$24.18Volume1.32 million shsAverage Volume713,482 shsMarket Capitalization$900.21 millionP/E RatioN/ADividend YieldN/APrice Target$31.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Viridian Therapeutics alerts: Email Address Viridian Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.82 Rating ScoreUpside/Downside121.4% Upside$31.20 Price TargetShort InterestHealthy12.52% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.72Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($3.97) to ($4.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.52 out of 5 starsMedical Sector426th out of 910 stocksMedical Laboratories Industry14th out of 18 stocks 4.4 Analyst's Opinion Consensus RatingViridian Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageViridian Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Viridian Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted12.52% of the outstanding shares of Viridian Therapeutics have been sold short.Short Interest Ratio / Days to CoverViridian Therapeutics has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Viridian Therapeutics has recently decreased by 5.77%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldViridian Therapeutics does not currently pay a dividend.Dividend GrowthViridian Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VRDN. Previous Next 3.2 News and Social Media Coverage News SentimentViridian Therapeutics has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Viridian Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for VRDN on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat Follows2 people have added Viridian Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Viridian Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.65% of the stock of Viridian Therapeutics is held by insiders.Read more about Viridian Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Viridian Therapeutics are expected to decrease in the coming year, from ($3.97) to ($4.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Viridian Therapeutics is -3.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Viridian Therapeutics is -3.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioViridian Therapeutics has a P/B Ratio of 2.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Viridian Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss Ratings“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.Learn these 4 simple steps and protect your savings before it’s too late. About Viridian Therapeutics Stock (NASDAQ:VRDN)Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.Read More VRDN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VRDN Stock News HeadlinesSeptember 4 at 8:33 PM | markets.businessinsider.comBuy Rating Affirmed for Viridian Therapeutics Amid Positive Outlook on VRDN-001 for Thyroid Eye DiseaseSeptember 4 at 2:03 AM | americanbankingnews.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Receives $31.20 Consensus Target Price from BrokeragesSeptember 7, 2024 | Weiss Ratings (Ad)“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.September 1, 2024 | americanbankingnews.comViridian Therapeutics (NASDAQ:VRDN) Stock Rating Reaffirmed by Needham & Company LLCAugust 31, 2024 | markets.businessinsider.comViridian Therapeutics’ VRDN-001 Shows Promise in TED Treatment: A Comprehensive Buy Rating AnalysisAugust 31, 2024 | markets.businessinsider.comViridian Therapeutics’ VRDN-001 Optimism: A Buy Rating Rooted in Superior Trial Results and Market PotentialAugust 30, 2024 | seekingalpha.comViridian Therapeutics: Key Inflection Points AheadAugust 30, 2024 | americanbankingnews.comViridian Therapeutics (NASDAQ:VRDN) Stock Rating Reaffirmed by Royal Bank of CanadaSeptember 7, 2024 | Weiss Ratings (Ad)“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.August 28, 2024 | markets.businessinsider.comViridian Therapeutics (VRDN) Gets a Buy from RBC CapitalAugust 18, 2024 | ca.finance.yahoo.comVRDN Jan 2025 7.500 putAugust 17, 2024 | ca.finance.yahoo.comVRDN Sep 2024 35.000 putAugust 17, 2024 | ca.finance.yahoo.comVRDN Oct 2024 15.000 putAugust 16, 2024 | benzinga.comDecoding 6 Analyst Evaluations For Viridian TherapeuticsAugust 14, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Viridian Therapeutics (VRDN), Solid Biosciences (SLDB)August 14, 2024 | markets.businessinsider.comBuy Rating for Viridian Therapeutics Backed by Strong Clinical Pipeline and Financial HealthAugust 13, 2024 | markets.businessinsider.comBuy Rating Affirmed: Viridian Therapeutics’ Upcoming Trials and Strong Pipeline Signal Substantial UpsideAugust 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Viridian Therapeutics Amid Positive Phase 3 Prospects and Strong Financial StandingSee More Headlines Receive VRDN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Viridian Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:VRDN CUSIPN/A CIK1590750 Webwww.viridiantherapeutics.com Phone(617) 272-4600Fax760-537-4101Employees50Year FoundedN/APrice Target and Rating Average Stock Price Target$31.20 High Stock Price Target$42.00 Low Stock Price Target$20.00 Potential Upside/Downside+121.4%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($4.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-237,730,000.00 Net Margins-79,185.77% Pretax Margin-79,185.77% Return on Equity-83.18% Return on Assets-44.82% Debt Debt-to-Equity Ratio0.05 Current Ratio15.82 Quick Ratio15.82 Sales & Book Value Annual Sales$310,000.00 Price / Sales2,903.90 Cash FlowN/A Price / Cash FlowN/A Book Value$5.16 per share Price / Book2.73Miscellaneous Outstanding Shares63,890,000Free Float63,407,000Market Cap$900.21 million OptionableOptionable Beta1.03 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Stephen F. Mahoney J.D. (Age 53)MBA, CEO, President & Director Dr. Eric N. Olson Ph.D.Co-Founder & Chairman of Scientific Advisory BoardDr. Michael R. Bristow M.D. (Age 79)Ph.D., Co-Founder & Member of the Scientific Advisory Board Dr. Marvin H. Caruthers Ph.D. (Age 84)Co-Founder & Scientific Advisory Board Member Mr. Vahe Bedian Ph.D.Co-Founder & Scientific AdvisorMr. Seth HarmonSenior VP of Finance and Accounting, Principal Financial & Accounting OfficerMr. Thomas W. Beetham J.D. (Age 54)MBA, Chief Operating Officer Ms. Jennifer Tousignant J.D.Chief Legal OfficerMr. John A. JordanVice President of Investor Relations & Corporate CommunicationsMr. Anthony Casciano (Age 47)Chief Commercial Officer More ExecutivesKey CompetitorsPsychemedicsNASDAQ:PMDArrowhead PharmaceuticalsNASDAQ:ARWRDicerna PharmaceuticalsNASDAQ:DRNAHims & Hers HealthNYSE:HIMSGuardant HealthNASDAQ:GHView All CompetitorsInsiders & InstitutionsNovo Holdings A SBought 900,000 shares on 8/20/2024Ownership: 3.134%Perceptive Advisors LLCSold 2,025,271 shares on 8/16/2024Ownership: 2.557%Algert Global LLCBought 17,673 shares on 8/16/2024Ownership: 0.087%Affinity Asset Advisors LLCBought 150,000 shares on 8/15/2024Ownership: 0.235%The Manufacturers Life Insurance Company Bought 7,450 shares on 8/15/2024Ownership: 0.050%View All Insider TransactionsView All Institutional Transactions VRDN Stock Analysis - Frequently Asked Questions How have VRDN shares performed this year? Viridian Therapeutics' stock was trading at $21.78 at the beginning of the year. Since then, VRDN shares have decreased by 35.3% and is now trading at $14.09. View the best growth stocks for 2024 here. How were Viridian Therapeutics' earnings last quarter? Viridian Therapeutics, Inc. (NASDAQ:VRDN) issued its quarterly earnings results on Thursday, August, 8th. The company reported ($1.02) earnings per share for the quarter, missing analysts' consensus estimates of ($0.87) by $0.15. The company had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.09 million. Viridian Therapeutics had a negative net margin of 79,185.77% and a negative trailing twelve-month return on equity of 83.18%. Who are Viridian Therapeutics' major shareholders? Top institutional investors of Viridian Therapeutics include Maverick Capital Ltd. (5.18%), Novo Holdings A S (3.13%), Perceptive Advisors LLC (2.56%) and Candriam S.C.A. (1.17%). Insiders that own company stock include Fairmount Funds Management Llc, Jonathan Violin, Scott Dunseth Myers, Lara Meisner, Barrett Katz and Life Sciences Public F Frazier. View institutional ownership trends. How do I buy shares of Viridian Therapeutics? Shares of VRDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VRDN) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viridian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viridian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.